TCF7L2 and malignant colon neoplasm: Knockdown of VBP1 also decreased TCF7L1 and TCF7L2 protein levels in Wnt-activated HCT116 colon cancer cells, which harbor an oncogenic mutation in β-catenin (Fig. 3H).